Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...
Zacks.com on MSN10h
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue EstimatesSage Therapeutics (SAGE) delivered earnings and revenue surprises of -7.59% and 11.20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...
Reports Q4 revenue $12.8M, consensus $14.4M. “We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is ...
Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report) and SAGE Therapeutics (SAGE – Research Report) with ...
Gilead Sciences, Inc. today announced that the company's Board of Directors has declared an increase of 2.6% in the company's quarterly cash dividend, beginning in the first quarter of 2025. The ...
Zacks.com on MSN19h
Biogen Gears Up to Report Q4 Earnings: What's in the Cards?Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
The Independent Medical Alliance (IMA), formerly the FLCCC, proudly announces the addition of nine distinguished senior fellows to its International Fellowship Program. This latest expansion brings ...
S&P 500 E-Mini futures (ESH25) are down -0.33%, andMarch Nasdaq 100 E-Mini futures (NQH25) are down -0.44% this morning as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback